Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 3/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30670260 | 1.00 | PDE2A (0.34) | PDE2APDE10APDK2PKLRRAF1 | |
| SCHEMBL24251561 | 0.77 | PDE2A (0.37) | PDE2APDE10AP2RX7 | |
| SCHEMBL30670274 | 0.77 | PDE2A (0.37) | PDE2APDE10AP2RX7 | |
| SCHEMBL30558736 | 0.75 | PDE2A (0.36) | PDE2APDE10A | |
| SCHEMBL25263069 | 0.75 | PDE2A (0.36) | PDE2APDE10A | |
| SCHEMBL30670248 | 0.69 | PDE2A (0.39) | PDE2APDE10A | |
| SCHEMBL26599210 | 0.69 | PDE2A (0.39) | PDE2APDE10A | |
| SCHEMBL26599261 | 0.68 | KMT2A (0.37) | PDE2APDE10AP2RX7 | |
| SCHEMBL30670230 | 0.68 | KMT2A (0.37) | PDE2APDE10AP2RX7 | |
| SCHEMBL2692167 | 0.67 | PKLR (0.40) | PDE10APDK2PKLRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339977-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-114075221-A | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339977-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | TYK2, JAK1, JAK3 | PDE2A 3552/4885PDE10A 2458/4885PDK2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.